PHARMACY

Ranbaxy to appeal generic Lipitor decision

BY Drew Buono

PRINCETON, N.J. Ranbaxy will appeal a Canadian court ruling that stopped the company from launching a generic version of Pfizer’s cholesterol drug Lipitor.

The decision will hold Ranbaxy from launching the generic until the patent expires on the brand in 2016.  The company in a statement said that, “Ranbaxy will appeal this decision and remains confident in its position.”

The company was looking to tap into Canada’s market for Lipitor, which has estimated sales of $800 million there. Ranbaxy, though, is still focused on other areas of the globe such as the U.S., Western Europe and Japan, which according to Vihari Purushothaman, a pharmaceutical analyst for Enam Securities, represents about 90 percent of the global market.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Roche to sue Teva over patent of Boniva

BY Allison Cerra

BASEL, Switzerland Swiss pharmaceutical company Roche Holding has filed suit against generic pharmaceutical maker Teva over Roche’s patented osteoporosis treatment, the company said Tuesday.

Roche filed a complaint at a New Jersey district court to prevent Teva from selling their generic version of Boniva, the company’s spokeswoman said.

Sales of Boniva for the first six months of the year totaled $314 million. Recently, Roche’s rival Novartis filed for an injunction against the generic pharmaceutical maker to halt the creation and production of its Famvir herpes treatment. Novartis was denied the injunction but was granted one by the U.S. District Court of Appeals a few days later. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

King Pharma announces intention to fight Actavis’ generic Avinza

BY Drew Buono

BRISTOL, Tenn. King Pharmaceuticals has recently learned that Actavis has filed paperwork with the Food and Drug Administration to make a generic version of their pain medication Avinza (morphine sulfate).

King “intends to vigorously enforce the patent on Avinza” by starting legal procedures that will most likely ending up with the two companies meeting in federal court.  King spokesman James Green said, “The business of generic manufacturers is to challenge as many patents as possible, hoping to win a few.”

At the beginning of the year King acquired all the rights to Avinza from Ligand Pharmaceuticals and has seen revenues of $9 million and $35 million in the first and second quarters of 2007.

Avinza’s patent does not end until Nov. 25, 2017.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?